Structure-Based Design, Optimization, and Development of [18F]LU13: A Novel Radioligand for Cannabinoid Receptor Type 2 Imaging in the Brain with PET.

The cannabinoid receptor type 2 (CB2R) is an attractive target for the diagnosis and therapy of neurodegenerative diseases and cancer. In this study, we aimed at the development of a novel 18F-labeled radioligand starting from the structure of the known naphthyrid-2-one CB2R ligands. Compound 28 (LU13) was identified with the highest binding affinity and selectivity versus CB1R (CB2RKi = 0.6 nM; CB1RKi/CB2RKi > 1000) and was selected for radiolabeling with fluorine-18 and biological characterization. The new radioligand [18F]LU13 showed high CB2R affinity in vitro as well as high metabolic stability in vivo. PET imaging with [18F]LU13 in a rat model of vector-based/-related hCB2R overexpression in the striatum revealed a high signal-to-background ratio. Thus, [18F]LU13 is a novel and highly promising PET radioligand for the imaging of upregulated CB2R expression under pathological conditions in the brain.

[1]  R. Maldonado,et al.  The CB2 cannabinoid receptor as a therapeutic target in the central nervous system , 2021, Expert opinion on therapeutic targets.

[2]  G. Bormans,et al.  Development of [18F]LU14 for PET Imaging of Cannabinoid Receptor Type 2 in the Brain , 2021, International journal of molecular sciences.

[3]  M. Vaas,et al.  In vivo Imaging of Cannabinoid Type 2 Receptors: Functional and Structural Alterations in Mouse Model of Cerebral Ischemia by PET and MRI , 2021, bioRxiv.

[4]  T. Darwish,et al.  Kinetic isotope effects and synthetic strategies for deuterated carbon-11 and fluorine-18 labelled PET radiopharmaceuticals. , 2021, Nuclear medicine and biology.

[5]  Steven H. Liang,et al.  Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development. , 2020, Journal of medicinal chemistry.

[6]  Anne-Caroline Schmöle,et al.  CB2 Receptor in Microglia: The Guardian of Self-Control , 2020, International journal of molecular sciences.

[7]  T. Woltering,et al.  Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors. , 2020, Journal of medicinal chemistry.

[8]  R. Meccariello.  Endocannabinoid System in Health and Disease: Current Situation and Future Perspectives , 2020, International journal of molecular sciences.

[9]  Yumin Zhang,et al.  Endocannabinoid Modulation of Microglial Phenotypes in Neuropathology , 2020, Frontiers in Neurology.

[10]  P. Brust,et al.  Studies towards the development of a PET radiotracer for imaging of the P2Y1 receptors in the brain: synthesis, 18F-labeling and preliminary biological evaluation. , 2019, European journal of medicinal chemistry.

[11]  W. Vanduffel,et al.  Preclinical evaluation of [18F]MA3: a CB2 receptor agonist radiotracer for PET , 2018, British journal of pharmacology.

[12]  S. Ametamey,et al.  Positron emission tomography of type 2 cannabinoid receptors for detecting inflammation in the central nervous system , 2018, Acta Pharmacologica Sinica.

[13]  Li Lin,et al.  Inflammatory Regulation by Driving Microglial M2 Polarization: Neuroprotective Effects of Cannabinoid Receptor-2 Activation in Intracerebral Hemorrhage , 2017, Front. Immunol..

[14]  Jie Wu,et al.  Brain cannabinoid receptor 2: expression, function and modulation , 2017, Acta Pharmacologica Sinica.

[15]  H. Feng,et al.  Cannabinoid receptor-2 stimulation suppresses neuroinflammation by regulating microglial M1/M2 polarization through the cAMP/PKA pathway in an experimental GMH rat model , 2016, Brain, Behavior, and Immunity.

[16]  T. Bisogno,et al.  Type-2 cannabinoid receptors in neurodegeneration. , 2016, Pharmacological research.

[17]  M. Pomper,et al.  Development of a High-Affinity PET Radioligand for Imaging Cannabinoid Subtype 2 Receptor. , 2016, Journal of medicinal chemistry.

[18]  G. Bormans,et al.  Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer’s disease , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  Ethan B. Russo.  Beyond Cannabis: Plants and the Endocannabinoid System. , 2016, Trends in pharmacological sciences.

[20]  Surjit Singh,et al.  Endocannabinoid System: A Multi-Facet Therapeutic Target. , 2016, Current clinical pharmacology.

[21]  S. Nabavi,et al.  Ligands for cannabinoid receptors, promising anticancer agents. , 2016, Life sciences.

[22]  Jeremiah A. Johnson,et al.  Loops versus Branch Functionality in Model Click Hydrogels , 2015 .

[23]  C. Mamat,et al.  Methods to Increase the Metabolic Stability of 18F-Radiotracers , 2015, Molecules.

[24]  P. Remy,et al.  Optimized Quantification of Translocator Protein Radioligand 18F-DPA-714 Uptake in the Brain of Genotyped Healthy Volunteers , 2015, The Journal of Nuclear Medicine.

[25]  S. Ametamey,et al.  Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor. , 2015, European journal of medicinal chemistry.

[26]  Brandie M. Ehrmann,et al.  CB2-Selective Cannabinoid Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides , 2014, Journal of medicinal chemistry.

[27]  E. D. Lange,et al.  Functions of the CB1 and CB2 Receptors in Neuroprotection at the Level of the Blood–Brain Barrier , 2014, NeuroMolecular Medicine.

[28]  J. Janjic,et al.  Cannabinoid CB2 receptor as a new phototherapy target for the inhibition of tumor growth. , 2014, Molecular pharmaceutics.

[29]  Vincenzo Micale,et al.  Therapeutic potential of cannabinoids in schizophrenia. , 2014, Recent patents on CNS drug discovery.

[30]  S. Ametamey,et al.  Synthesis and Preliminary Evaluation of a 2-Oxoquinoline Carboxylic Acid Derivative for PET Imaging the Cannabinoid Type 2 Receptor , 2014, Pharmaceuticals.

[31]  G. Martinotti,et al.  The Endocannabinoid System: A Putative Role in Neurodegenerative Diseases , 2013, International journal of high risk behaviors & addiction.

[32]  Jonas Eriksson,et al.  Radiation Dose of the P-Glycoprotein Tracer 11C-Laniquidar , 2013, The Journal of Nuclear Medicine.

[33]  S. Ametamey,et al.  Radiolabeling and in vitro /in vivo evaluation of N‐(1‐adamantyl)‐8‐methoxy‐4‐oxo‐1‐phenyl‐1,4‐dihydroquinoline‐3‐carboxamide as a PET probe for imaging cannabinoid type 2 receptor , 2013, Journal of neurochemistry.

[34]  C. Silvestri,et al.  The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. , 2013, Cell metabolism.

[35]  G. Bormans,et al.  Preclinical evaluation of [11C]NE40, a type 2 cannabinoid receptor PET tracer. , 2012, Nuclear medicine and biology.

[36]  G. Bormans,et al.  A PET Brain Reporter Gene System Based on Type 2 Cannabinoid Receptors , 2011, The Journal of Nuclear Medicine.

[37]  Dorota Latek,et al.  Modeling of ligand binding to G protein coupled receptors: cannabinoid CB1, CB2 and adrenergic β2AR , 2011, Journal of molecular modeling.

[38]  D. Finn,et al.  Brain CB2 Receptors: Implications for Neuropsychiatric Disorders , 2010, Pharmaceuticals.

[39]  P. Reggio.  Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. , 2010, Current medicinal chemistry.

[40]  Í. Azcoitia,et al.  Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. , 2009, Brain : a journal of neurology.

[41]  E. Masini,et al.  Rational design, synthesis, and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists. , 2009, Journal of medicinal chemistry.

[42]  P. Harrison,et al.  A Novel Method for Determination of the Affinity of Protein: Protein Interactions in Homogeneous Assays , 2008, Journal of biomolecular screening.

[43]  V. Adhami,et al.  Cannabinoids for cancer treatment: progress and promise. , 2008, Cancer research.

[44]  J. Romero,et al.  Cannabinoid CB2 receptors in human brain inflammation , 2008, British journal of pharmacology.

[45]  Paul F. Smith,et al.  Expression of the cannabinoid CB2 receptor in the rat cerebellum: An immunohistochemical study , 2006, Neuroscience Letters.

[46]  H. Pajouhesh,et al.  Medicinal chemical properties of successful central nervous system drugs , 2005, NeuroRX.

[47]  Alberto Rábano,et al.  Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains , 2003, The Journal of Neuroscience.

[48]  R. Waterhouse,et al.  Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[49]  T. Vanderah,et al.  CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? , 2003, Current opinion in pharmacology.

[50]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[51]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[52]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[53]  G. Giovannoni,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Biology of Cannabis the Cannabinoid System the Therapeutic Potential of Cannabis , 2022 .